Table 4. Spearman Correlations Among ERP and Symptom Change Scores.
| Post-infusion difference score (0.03 mg/kg THC—placebo) | 1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 | 10 | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | P3b amplitude | — | |||||||||
| 2 | P3a amplitude | 0.368† | — | ||||||||
| 3 | P3b latency | −0.013 | −0.417* | — | |||||||
| 4 | P3a latency | −0.255 | −0.89 | −0.218 | — | ||||||
| 5 | PANSS positive | −0.259 | −0.242 | −0.112 | −0.029 | — | |||||
| 6 | PANSS negative | −0.126 | 0.189 | −0.189 | −0.142 | 0.210 | — | ||||
| 7 | PANSS general | −0.192 | −0.073 | −0.154 | 0.101 | 0.611** | 0.617** | — | |||
| 8 | PANSS total | −0.217 | −0.066 | −0.095 | 0.029 | 0.620** | 0.774** | 0.948** | — | ||
| 9 | CADSS-CR | −0.055 | 0.220 | −0.135 | −0.015 | 0.340 | 0.685** | 0.812** | 0.807** | — | |
| 10 | CADSS-PR | −0.431* | 0.022 | −0.130 | 0.305 | 0.632** | 0.451* | 0.760** | 0.751** | 0.622** | — |
Note: †p<0.10; *p<0.05; **p<0.01.